ClinicalTrials.gg
Sign In
Not yet recruitingNCT07909720Updated Nov 4, 2026

The EYERISING Study

An interventional study of Repeated Low-Level Red Light (RLRL) therapy and Placebo Device in Myopia, Astigmatism and Anisometropia, sponsored by University of Wisconsin, Madison. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Treatment

Updated Nov 4, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
333
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Study summary

The purpose of this clinical trial is to see if and how well Repeated Low-Level Red Light (RLRL) therapy works to control myopia over 12 months. The main question it aims to answer is:

  • Can RLRL therapy help slow down the worsening of myopia?

Participants will use a red-light therapy investigational device at home, 5 days a week for 12 months.

02

Conditions studied

  • Myopia
  • Astigmatism
  • Anisometropia
03

In context

Myopia

1,010 studies on the registry are indexed under Myopia; 212 are open to participants now.

This study's planned enrollment of 333 is above the median of 80 across 804 interventional studies indexed under Myopia.

Browse Myopia studies →

Lead sponsor

University of Wisconsin, Madison is the lead sponsor of 1,187 studies on the registry; 182 are open to participants now.

Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.

Browse University of Wisconsin, Madison studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 6 and ≤ 12 (at screening)
  • Myopia: Cycloplegic SER -1.0 to -7.0 D
  • Astigmatism: \< 1.5 D
  • Anisometropia: \< 1.5 D
  • Informed parental consent
  • Consistent access to wireless internet

Exclusion criteria

Exclusion Criteria:

  • A subject who is born female and who is currently menstruating or has begun menstruation (menarche).

    • Ophthalmic diseases, conditions, or syndromes other than refractive errors
    • Previous use of treatment for myopia control (e.g., defocusing lenses or contact lenses, orthokeratology, atropine, and pirenzepine)
    • Any previous ocular surgery
    • Systemic diseases (e.g., endocrine, cardiac diseases) and developmental anomalies
    • Inability to attend regular follow up visits
    • Participants with any symptom, disease, or other condition that, in the opinion of the investigators, may affect the effectiveness of the investigational treatment and/or the ability of the participant to complete study activities
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
333 participants (estimated)

Study arms

  • Experimental
    Red light therapy

    Participants will receive red light therapy

    Device: Repeated Low-Level Red Light (RLRL) therapy

  • Placebo comparator
    Placebo

    Participants will receive placebo therapy

    Device: Placebo Device

Interventions

  • DeviceRepeated Low-Level Red Light (RLRL) therapy

    RLRL device emits low-level red-light with a wavelength of 650 ± 10 nm. The device provides light at a power of 2.00 ± 0.50 mW.

  • DevicePlacebo Device

    Placebo device will match the RLRL in appearance but will not emit light.

06

What researchers measure

Primary outcomes

  1. Change in cycloplegic spherical equivalent refraction (SER)

    SER will be measured using an autorefractometer after eye drops are given to temporarily relax the eye's focusing muscles. SER, measured in diopters (D), represents the amount of nearsightedness and will be used to measure the change in myopia from baseline.

    Time frame: Baseline, 4 months, 8 months, 12 months

  2. Change in axial length (AL)

    AL will be measured using the IOLMaster and reported in millimeters (mm). Change in AL from baseline will be used to assess ocular growth/myopia progression.

    Time frame: Baseline, 4 months, 8 months, 12 months

Secondary outcomes

  1. Change in rate of SER increase

    Time frame: Baseline, 4 months, 8 months, 12 months

  2. Change in rate of AL increase

    Time frame: Baseline, 4 months, 8 months, 12 months

  3. Best corrected visual acuity (BCVA)

    Time frame: Baseline, 4 months, 8 months, 12 months

  4. Change in National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) composite score

    The NEI VFQ-25 is a 25-item questionnaire assessing vision-related functioning and quality of life. The composite score ranges from 0 to 100, with higher scores indicating better visual functioning and vision-related quality of life.

    Time frame: Baseline, 4 months, 8 months, 12 months

  5. Change in anterior chamber depth (ACD)

    Time frame: Baseline, 4 months, 8 months, 12 months

  6. Change in corneal curvature (CC)

    Time frame: Baseline, 4 months, 8 months, 12 months

  7. Change in choroidal thickness (CT)

    Time frame: Baseline, 4 months, 8 months, 12 months

  8. Change in White-to-White (WTW)

    Time frame: Baseline, 4 months, 8 months, 12 months

  9. Change in choroidal structures

    Time frame: Baseline, 4 months, 8 months, 12 months

  10. Intraocular pressure (IOP)

    Time frame: Baseline, 4 months, 8 months, 12 months

  11. Ocular and systemic symptoms

    Time frame: Baseline, 4 months, 8 months, 12 months

  12. Ocular signs assessed by slit-lamp biomicroscopy and binocular indirect ophthalmoscopy

    Time frame: Baseline, 4 months, 8 months, 12 months

07

Study locations

2 sites
  • University of Wisconsin - Madison
    Madison, Wisconsin 53715, United States
    • Angie Adler · Contactamadler1@wisc.edu · 608-265-7557
    • Yasmin Bradfield, MD · Principal investigator
  • Tilganga Institute of Ophthalmology
    Kathmandu, Bagmati Province, Nepal
    • Srijana Adhikari · Contactsrij_a@yahoo.com
    • Srijana Adhikari · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for May 2029, 29 months later.

Of 196 non-industry interventional studies with no phase under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 46. This study's planned 29 months is above that.

Counting every sponsor, half of 381 studies reached it within 19 months; a quarter within 5 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: start Oct 2026 → Dec 2026, primary completion Mar 2029 → May 2029 and completion Mar 2029 → May 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 2, 2026
StartEst.
Dec 2026was Oct 2026
Primary completionEst.
May 2029was Mar 2029
CompletionEst.
May 2029was Mar 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Dec 2026
Nov 4, 2026
Primary completion
Mar 2029→May 2029
Nov 4, 2026
Study completion
Mar 2029→May 2029
Nov 4, 2026
Registered
First appeared on the registry
Nov 2, 2026
Show all 2 updates
  1. Nov 4, 2026
    Start date Oct 2026→Dec 2026
    Primary completion Mar 2029→May 2029
    Study completion Mar 2029→May 2029
  2. Nov 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07909720
Lead sponsor
University of Wisconsin, Madison
Responsible party
Sponsor
First posted
Nov 2, 2026
Start date
Dec 2026 (estimated)
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Angie Adler
Contact
amadler1@wisc.edu
608-265-7557
Yasmin Bradfield, MD
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Myopia →

Other studies from this sponsor

University of Wisconsin, Madison →

Start the discussion